Chad and Senegal are two of the eight pioneer countries of Rays of Hope, the IAEA initiative to increase access to radiotherapy for cancer patients in low- and middle-income countries. Nine months into the initiative, Chad is making preparations for its first cancer therapy centre in N’Djamena and plans to launch its National Cancer Control Plan (NCCP) in early 2023, while Senegal has recently completed its NCCP, detailing an ambitious national objective to scale-up cancer care outside Dakar, in particular increasing access in Diamniadio.
Improving access to cancer care in Senegal
Today, there are four operational linear accelerators — the machine most commonly used to deliver radiotherapy to cancer patients — in Senegal, each of which has a capacity to treat approximately 30 patients a day, under normal conditions. The country is also expanding its nuclear medicine services with a plan to serve other countries in the west Africa region. The IAEA has supported Senegal in the evolution of its programme on cancer care, including upgrading from 2D to 3D radiotherapy and brachytherapy in 2019, which has the benefit of producing more individualized patient treatment, better clinical outcomes and reduced side effects.
In May 2022, at an event marking a pivotal milestone for Senegal, more than 50 national professionals from hospitals, public administration and civil society participated in the official validation of the national NCCP for 2022-2025, alongside IAEA officials and international experts in cancer control.
“The development and adoption of this new NCCP allows the government of Senegal to identify the priorities for cancer prevention and control,” said Dr Babacar Gueye, Director of the Senegalese Ministry of Health’s Directorate for Disease Control. “In particular, this plan will guide us in allocating the necessary resources to reactivate the cancer registry and to advance the decentralisation of radiotherapy services.
Furthermore, by defining the baseline and the targets for the next five years, we will be able to monitor and evaluate the progress of our capacity to scale-up the access to cancer diagnosis and treatment to the whole country.”